海尔生物公告，第三季度营收为5.66亿元，同比增长1.24%；净利润为5565.17万元，同比下降25.60%。 前三季度营收为17.61亿元，同比下降1.17%；净利润为1.98亿元，同比下降35.83%。 ...

Core Viewpoint - The article discusses the importance and development factors of platelet constant temperature oscillating storage boxes, highlighting their role in ensuring the safety and effectiveness of clinical blood transfusions through advanced temperature control and oscillation technology [2][4]. Group 1: Definition and Importance - Platelet constant temperature oscillating storage boxes are medical devices that maintain a stable temperature environment to preserve platelet activity, ensuring safe and effective blood transfusions [2]. - These devices prevent platelet aggregation and sedimentation, maintaining uniform distribution and functional integrity, and are equipped with temperature sensors and alarm systems for real-time monitoring [2]. Group 2: Development Factors - The growth of platelet constant temperature oscillating storage boxes is driven by factors such as aging population, improved medical standards, increased surgical procedures, regulatory requirements, public health emergencies, and technological integration [4]. - The aging population, particularly in emerging economies like China, is leading to a rigid increase in clinical blood demand, especially for platelet transfusions during surgeries [5]. Group 3: Quality and Safety Requirements - Advances in medical technology have raised the performance requirements for storage boxes, necessitating precise temperature control and oscillation parameters to accommodate new storage solutions [7][8]. - The emphasis on green healthcare has led to the adoption of low-power motors and environmentally friendly refrigerants, enhancing sustainability and user-friendliness [8]. Group 4: Regulatory and Public Health Considerations - Stricter regulations on blood product management are pushing the development of high-precision and reliable storage boxes, requiring compliance with quality management standards [9]. - The COVID-19 pandemic highlighted vulnerabilities in the blood supply chain, prompting the need for larger, intelligent storage solutions to ensure adequate platelet reserves during emergencies [10]. Group 5: Future Trends - The future of platelet constant temperature oscillating storage boxes is expected to focus on smart and digital transformation, with over 70% of market products projected to integrate AI-driven predictive maintenance and real-time data analysis by 2027 [11]. - There is a strategic shift towards integrated solutions that encompass the entire blood management process, with expectations that this model will account for over 60% of market share by 2028 [12]. - The market for portable storage boxes is anticipated to grow significantly, driven by the increasing demand for emergency medical services and mobile blood banks [13]. Group 6: Industry Leaders - Qingdao Haier Biomedical is a leader in the field, providing innovative digital solutions for blood safety management, with a reported annual revenue of 2.284 billion yuan in 2024 [15]. - Haier's platelet constant temperature oscillating storage boxes are designed to meet stringent storage requirements, integrating IoT technology for enhanced monitoring and data traceability [15][16].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 会议召开时间：2025年10月31日(星期五)上午11:00-12:00 ● 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） ● 会议召开方式：上证路演中心网络互动 ● 投资者可于2025年10月24日（星期五）至10月30日（星期四）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱haierbiomedical@haierbiomedical.com进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 青岛海尔生物医疗股份有限公司（以下简称"公司"）将于2025年10月31日发布公司2025年第三季度报 告，为便于广大投资者更全面深入地了解公司2025年第三季度经营成果、财务状况，公司计划于2025年 10月31日（星期五）11:00-12:00举行2025年第三季度业绩说明会，就投资者关心的问题进行交流。 一 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-048 青岛海尔生物医疗股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 会议召开时间：2025 年 10 月 31 日(星期五)上午 11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址： 二、 说明会召开的时间、地点 （一） 会议召开时间：2025 年 10 月 31 日 （星期五） 11:00-12:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 24 日（星期五）至 10 月 30 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 haierbiomedical@haierbiomedical.com 进行提问。公司将在说明会上对投资者 普遍关注的问题 ...

Core Viewpoint - Haier Biomedical's major shareholder, Qingdao Guoxin Financial Holdings Co., Ltd., has increased its stake, reflecting confidence in the future of the life sciences industry and recognition of Haier Biomedical's governance, industry position, business capabilities, operational results, and risk management [1] Group 1: Shareholder Information - The controlling shareholder of the increased stake is Qingdao Guoxin Financial Holdings Co., Ltd., with actual control by the State-owned Assets Supervision and Administration Commission of the Qingdao Municipal People's Government [1] - The investment is based on the shareholder's long-term positive outlook on the life sciences sector and the company's performance [1] Group 2: Future Plans and Strategies - Haier Biomedical aims to deepen its focus on four major industries and enhance the integration of AI technology with life sciences and medical innovation scenarios [1] - The company plans to accelerate its globalization process to provide returns to investors [1]

作为国内生物医疗低温存储设备龙头企业，海尔生物2025年上半年实现归母净利润1.43亿元，已构建起 低温存储、智慧用药、血液技术、实验室解决方案四大产业协同发展格局，其中新产业收入占比攀升至 47%，成为驱动业绩增长的核心引擎。各细分领域表现亮眼：智慧用药业务市占率跻身行业前三，近期 成功开拓东南亚市场；血液技术产业市占率超50%，以"设备+耗材+服务"的商业模式持续打开盈利空 间；实验室解决方案在国产替代浪潮中保持多项产品份额领先，AI赋能自动化方案显著提升行业运营 效率；传统优势业务低温存储稳居行业第一，海外25个国家份额领跑，欧洲、亚太区域收入实现高双位 数增长，全球化布局成效逐步显现。 值得一提的是，海尔生物实控人海尔集团与蚂蚁集团近期达成全面战略合作，计划推动医疗健康服务的 数字化升级。海尔生物作为集团大健康生态的重要组成部分，有望在智慧实验室、生物安全数字化等领 域承接协同资源，迎来新的增长动能。 在生命科学行业加速发展与全球化深化的双重机遇下，久实优选1号的增持计划，既是国资资本对海尔 生物技术壁垒与增长潜力的认可，也为市场传递积极信号，有望进一步提振投资者信心，为公司长期发 展注入更强动力。（ ...

Core Viewpoint - The announcement details that Qingdao Jiushi Investment Management Co., Ltd. has increased its stake in Haier Biomedical to 5% without triggering a mandatory takeover bid [2][3]. Group 1: Shareholding Changes - Jiushi Youxuan No. 1 Private Securities Investment Fund acquired 15,897,909 shares of Haier Biomedical from August 14, 2024, to October 14, 2025, representing 5% of the total share capital [4][10]. - The increase in shareholding does not change the company's controlling shareholder or actual controller [3][5]. Group 2: Investment Rationale - The investment is based on confidence in the future development of the life sciences industry and recognition of Haier Biomedical's governance, industry position, business capabilities, operational results, and risk management [10]. - Jiushi Youxuan No. 1 has no current plans to increase or decrease its stake in the next 12 months [11]. Group 3: Compliance and Reporting - The report complies with relevant laws and regulations, including the Securities Law and the Management Measures for the Acquisition of Listed Companies [7][12]. - The report confirms that the information disclosed is accurate and complete, with no misleading statements or omissions [12].

Core Viewpoint - Haier Biomedical has been targeted for a stake acquisition by Jiushi Investment, reaching a 5% shareholding threshold, indicating confidence in the company's future development and potential for collaborative growth [1][4][2]. Group 1: Investment Details - Jiushi Investment's Jiushi Preferred No. 1 Fund acquired 15,897,900 shares of Haier Biomedical, representing 5% of the total share capital [4]. - The investment was made through secondary market transactions and was funded by Jiushi Investment's own capital [4]. - Jiushi Investment has no immediate plans to increase or decrease its stake in Haier Biomedical within the next 12 months [4]. Group 2: Company Background - Haier Biomedical is a subsidiary of Haier Group's health ecosystem brand, established in October 2005 and listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in October 2019 [7]. - The company has faced a continuous decline in stock price over the past four years, with significant drops of 29.83%, 35.46%, 12%, and 6.38% in the years 2022, 2023, 2024, and 2025 respectively [10]. Group 3: Financial Performance - In the first half of 2025, Haier Biomedical reported revenue of 1.196 billion yuan, a decrease of 2.27% year-on-year, and a net profit of 143 million yuan, down 39.09% year-on-year [8]. - The company attributes the profit decline to external factors, new capacity ramp-up, and strategic investments, but anticipates improvement as industry conditions recover [8]. - The overseas business showed strong growth, with revenue of 427 million yuan, a year-on-year increase of 30.17%, achieving the highest quarterly revenue and growth rate since 2023 in the second quarter [9].

登录新浪财经APP 搜索【信披】查看更多考评等级 签署日期：2025年10月15日 四、本次权益变动是根据本报告所载明的资料进行的。信息披露义务人没有委托或者授权其他任何人提 供未在报告书中列载的信息和对本报告书做出任何解释或者说明。 五、信息披露义务人承诺本报告书不存在虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性、 完整性承担法律责任。 第一节 释义 除非特别说明，下列简称在本报告书中具有如下含义： 信息披露义务人声明 一、本信息披露义务人根据《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司收购管理 办法》（以下简称"《收购办法》"）《公开发行证券公司信息披露内容与格式准则第15号——权益变动 报告书》（以下简称"《准则15号》"）等相关的法律、法规及规范性文件编写本报告书。 二、信息披露义务人签署本报告已获得必要的授权和批准，其履行亦不违反信息披露义务人内部规则中 的任何条款，或与之相冲突。 三、依据《证券法》《收购办法》《准则15号》规定，本报告书已全面覆盖信息披露义务人在青岛海尔 生物医疗股份有限公司（以下简称"海尔生物"或"公司"）中拥有权益的股份变动情况。 截至本报告书签署日， ...

Core Viewpoint - The announcement details that Qingdao Jiushi Investment Management Co., Ltd. has increased its stake in Qingdao Haier Biomedical Co., Ltd. to 5% through market transactions, reflecting confidence in the company's future development and long-term investment value [2][4]. Group 1: Shareholding Changes - Jiushi Youxuan No. 1 Private Securities Investment Fund acquired 15,897,909 shares of Haier Biomedical, representing 5% of the total share capital, between August 14, 2024, and October 14, 2025 [4][14]. - The increase in shareholding does not trigger a mandatory tender offer [2][5]. - The change in shareholding will not alter the company's controlling shareholder or actual controller [3][5]. Group 2: Investment Rationale - The investment is based on the belief in the future prospects of the life sciences industry and recognition of Haier Biomedical's performance in governance, industry position, business capabilities, operational results, and risk management [11]. - The funding for the share acquisition comes from Jiushi Youxuan's own capital [4][14]. Group 3: Future Plans - As of the report's signing date, there are no specific plans or agreements for further increasing or decreasing the stake in the next 12 months [13].